Coexistence of Histologically Confirmed Hashimoto's Thyroiditis with Different Stages of Papillary Thyroid Carcinoma in a Consecutive Chinese Cohort by Liu, Xiaoyun et al.
 
Coexistence of Histologically Confirmed Hashimoto's Thyroiditis
with Different Stages of Papillary Thyroid Carcinoma in a
Consecutive Chinese Cohort
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Liu, X., L. Zhu, D. Cui, Z. Wang, H. Chen, Y. Duan, M. Shen, et
al. 2014. “Coexistence of Histologically Confirmed Hashimoto's
Thyroiditis with Different Stages of Papillary Thyroid Carcinoma
in a Consecutive Chinese Cohort.” International Journal of
Endocrinology 2014 (1): 769294. doi:10.1155/2014/769294.
http://dx.doi.org/10.1155/2014/769294.
Published Version doi:10.1155/2014/769294
Accessed February 17, 2015 8:15:57 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13581144
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAResearch Article
Coexistence of Histologically Confirmed Hashimoto’s
Thyroiditis with Different Stages of Papillary Thyroid
Carcinoma in a Consecutive Chinese Cohort
Xiaoyun Liu,
1 Lijun Zhu,
2 Dai Cui,
1 Zhixiao Wang,
1 Huanhuan Chen,
1
Yu Duan,
1 Meiping Shen,
3 Yunsong Wu,
4 Rong Rong,
4 Zhihong Zhang,
4 Xiaodong Wang,
1
Jiawei Chen,
1 Erik K. Alexander,
5 and Tao Yang
1
1 Department of Endocrinology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
2Department of Children’s Health Care, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University,
Nanjing, Jiangsu 210029, China
3Department of Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
4Department of Pathology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
5Thyroid Unit, Division of Endocrinology, Metabolism and Diabetes, Department of Medicine,
Brigham & Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA
Correspondence should be addressed to Tao Yang; yangt@njmu.edu.cn
Received 31 May 2014; Revised 25 October 2014; Accepted 4 November 2014; Published 18 November 2014
Academic Editor: Jack R. Wall
Copyright © 2014 Xiaoyun Liu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose. To determine the relationship between Hashimoto’s thyroiditis (HT) and all stages of papillary thyroid carcinoma
(PTC) with or without local lymph node metastasis (LNM). Methods. We conducted a retrospective study of thyroidectomies
from 2008–2013 in First Affiliated Hospital of Nanjing Medical University. We categorized patients according to the presence of
histopathologically proven HT. The prevalence of mPTC (maximum diameter ≤ 10mm) and crPTC (clinical relevant PTC) and
localLNMrateswerecompared.Results.Weevaluated6,432consecutivethyroidectomies.Intotal,1,328specimenswereconfirmed
as HT. The prevalence of PTC in this HT cohort was 43.8%, significantly higher than non-HT group. After adjustment of gender
a n da g e ,t h ep r e v a l e n c eo fP T Cw a ss t i l lh i g h e ri nH Tg r o u p .H Tw a sar i s kf a c t o rf o rP T Ci nm u l t i v a r i a t ea n a l y s i sw i t ho d d s
ratio 2.725 (95% CI, 2.390–3.109) (𝑃 < 0.001). However, no correlation was found between HT and LNM of PTC. Conclusion.H T
was associated with an increased prevalence of all stages of PTC, independent of tumor size, gender, and age. In contrast, locally
advanced disease defined by LNM was unrelated to HT. These data suggest an association of HT with low risk PTC and a potential
protective immunologic effect from further disease progression.
1. Introduction
Thyroid cancer is the most common endocrine malignancy
worldwide, with a significant increase in global incidence [1–
4] over the past decade. This is true both in the United States
[2, 5] and in eastern Asia including China [6–9]. About 70%
to 80% of thyroid cancers are papillary thyroid carcinoma
(PTC)[9,10].Despitesurgicaladvancesandbetterlong-term
results,however,theunderlyingpathogenesisofPTCremains
unclear.
Hashimoto’s thyroiditis (HT) has been postulated to
have a causative relationship to PTC, being suggested as a
possible risk factor for developing PTC. This link was first
proposed in 1955 with several subsequent retrospective stud-
ies showing similar results [11–15]. The exact mechanism
remains uncertain. Some studies suggest that stimulating
TSH concentrations (often mildly elevated) may be one res-
ponsible factor for this relationship [16]. In support, treat-
ment with L-T4 m a yr e d u c eT S Hl e v e l sa n dd e c r e a s e st h e
prevalence of clinically detectable PTC [12]. However, other
studies are contradictory finding TSH concentration similar
among patients regardless of PTC or benign disease [17].
ItiswellknownthatPTCrepresentsaspectrumofdisease
inclusive of heterogeneity and severity in histologic patterns
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and/or tumor stages. Occult or microscopic PTC (mPTC) is
frequently incidentally detected in histologic samples even
when benign nodules are assumed. It is uncertain whether
incidental micro-PTC (mPTC) simply represents an early
s t a g eo fo v e r t( o rc l i n i c a l l yr e l e v a n t )P T Co ri sa c t u a l l y
a different subtype of PTC which seldom progresses. It is
therefore reasonable to postulate that the analysis of PTC as
au n i fi eds i n gl egr o u pm a yi npa rtber e s po n s i b l ef o rth ec o n -
fl i c t i n gp u b l i s h e dd a t a .N o t a b l y ,m o s tp r e v i o u ss t u d i e so n l y
evaluated clinically relevant PTC (crPTC, maximum diame-
ter > 1cm in size). We hypothesize that mPTC might be the
e a r l ys t a g eo fc r P T Cw i t hs i m i l a rr e l a t i o n s h i p se x i s t i n g
between mPTC and HT when compared to crPTC and HT.
However, some evidence suggests that the presence of HT
m a yb ea s s o c i a t e dw i t hl e s sr i s ko fP T Cl y m p hn o d em e t a s -
tasis (LNM) and an overall better prognosis [11, 18]. To
elucidatetheuncertaintyastotheinfluenceofHTuponlocal
tumor growth (even from a very early stage), we conducted a
retrospective study trying to clarify the relationship between
HT and different stages of PTC.
2. Methods
We collected data from the Register and Reporting system
in Department of Pathology, the First Affiliated Hospital
of Nanjing Medical University. Particularly, we reviewed all
consecutive thyroid histopathological reports from January
2008 to December 2013. Patient demographic data was
obtainedbychartreviewatacentrallocationbyXiaoyunLiu,
Lijun Zhu, Dai Cui, Zhixiao Wang, Huanhuan Chen, Yu
Duan, Xiaodong Wang, and Jiawei Chen.
Generally, thyroidectomies were performed for the fol-
lowingreasons:(a)worrisomefindingsfromultrasonography
and/or abnormal lymph node enlargement, (b) malignancy
suspected from previous thyroid FNA, or inconclusive FNA
results, (c) patients with multiple or bilateral nodules or
symptoms of neck or throat compression, or enlargement
during follow-up, and (d) concerning clinical or physical
examination findings warranting consideration for removal.
A small minority of patients chose thyroidectomy at their
own wish, primarily for cosmetic reasons.
Malignancy, if present, was reported as one of the follow-
ingsubtypes:crPTC,withthemaximumdiameterlargerthan
10mm; mPTC, with the maximum diameter less than or
e q u a lt o1 0m m[ 19, 20]; follicular thyroid carcinoma (FTC);
medullary thyroid carcinoma (MTC); and anaplastic thyroid
carcinoma (ATC). For each case, we collected data confirm-
ingthemaximumdiameterofthetumor,tumormultifocality,
and other pathologic features. The impact of Hashimoto’s
thyroiditis upon mPTC and crPTC rates was the primary
focus of this investigation. Papillary structures sometimes
seen in nodular hyperplasia were not recorded as PTC. All
pathological findings were confirmed by three experienced
endocrine pathologists (Yunsong Wu, Rong Rong, and Zhi-
hong Zhang).
Lymphnodedissectionwasperformedatthediscretionof
t h es u r g e o nb a s e du p o nc l i n i c a la n do t h e rf a c t o r sa c c o r d i n g
t ot h eg u i d e l i n ef r o mt h eA m e r i c a nTh y r o i dA s s o c i a t i o n
(ATA) [21]. Most often, a neck ultrasound or computed
tomography(CT)scanwasperformedpriortosurgeryallow-
ing assessment of neck adenopathy. Frozen sections were
routinely used to guide the extent of the surgical procedures.
I ft h en o d u l ew a sf o u n dt ob em a l i g n a n tb yf r o z e ns e c t i o n
and no abnormal lymph nodes were identified on preoper-
ative imaging (or during the surgery), an ipsilateral central
lymph node dissection (CLND) from level VI was generally
performed. Only when the tumor size was within 10mm and
no abnormal lymph node was found during the operation,
CLND was not routinely performed. If abnormal lymph
nodes were identified during preoperative ultrasound or
intraoperatively, and the snap-frozen sample showed malig-
nantlesion,amodifiedlaterallymphnodedissection(LLND)
was performed. All the samples were formalin fixed paraffin
embedded (FFPE) for final histopathology confirmation.
The histologic diagnosis of HT was made according to
accepted standards [18]. HT was defined as the presence of
diffuse lymphocytic infiltration with the formation of lym-
phoid follicles and the presence of reactive germinal centers;
the infiltrate had to occur in a normal region of the thyroid
gland, distinct from the site of the thyroid carcinoma. Peri-
tumoural inflammatory response and small areas of lympho-
cytic infiltration were not designated as HT. The diagnosis
of HT was solely made upon the histological findings. The
antithyroglobulin and antithyroid peroxidase antibody levels
were not routinely measured for the diagnosis of HT.
We recruited 6,432 cases with valid pathology reports
including all thyroidectomies performed over the six-year
period. We next categorized each according to the histologic
diagnosisofHTandseparatelyfortheidentificationofmPTC
and crPTC (or other cancer types).
Quantitative data are shown as mean ± SD, compared
using independent samples 𝑡-test, whereas numbers and
percentageareprovidedforqualitativedata.Percentageswere
compared using the 𝜒
2 test. The odds ratio (OR) and the
95% confidence interval (CI) for relationships between each
variableandPTCorpositiveLNM(yesorno)werecalculated
usingbinarylogisticregression.Alltestswere2-sided,anda𝑃
value <0.05 was considered statistically significant. Statistical
analyses were performed with SPSS software, version 13.0 for
Windows (SPSS Inc., Chicago, IL, USA).
This study was reviewed and deemed exempt from writ-
teninformedconsentbytheInstitutionalReviewBoard(IRB)
of the First Affiliated Hospitalof Nanjing Medical University.
It was approved by the IRB for analysis.
3. Results
3.1. Basic Characteristics and Thyroid Carcinoma Distribution
of Non-HT and HT Groups. Over a 6-year period, we
evaluated 6,432 consecutive patients who underwent thy-
roidectomy. Demographic and pathologic details for all
subjects are shown in Table 1.A m o n gt h i sc o h o r t ,2 0 . 6 %
(1,328/6,432) of our thyroidectomy population was histolog-
ically confirmed to have HT. Not surprisingly, those with
HT were disproportionately female, consistent with other
autoimmune illnesses. The mean age of the HT cohort wasInternational Journal of Endocrinology 3
Table 1: Baseline characteristics and thyroid carcinoma distribution between non-HT and HT groups.
Non-HT (𝑛 = 5104) HT (𝑛 =1 3 2 8 ) 𝜒
2 𝑃
Age at diagnosis 48.72 ± 13.74 46.21 ± 13.55 <0.01
<45y (𝑛 = 2565) 1972 (38.6%) 593 (44.7%) 15.914 <0.01
⩾45y (𝑛 = 3867) 3132 (61.4%) 735 (55.3%)
Gender
Male (𝑛 = 1373) 1274 (25.0%) 99 (7.5%) 192.350 <0.01
Female (𝑛 = 5059) 3830 (75.0%) 1229 (92.5%)
PTC (𝑛 = 1722) 1141 (22.4%) 581 (43.8%) 246.051 <0.01
mPTC (𝑛 = 823) 541 (10.6%) 282 (21.2%) 106.826 <0.01
crPTC (𝑛 = 899) 600 (11.8%) 299 (22.5%) 101.467 <0.01
FTC (𝑛 = 115) 97 (1.9%) 18 (1.4%) 1.783 0.18
MTC (𝑛 = 34) 26 (0.5%) 8 (0.6%) 0.173 0.68
ATC (𝑛 = 4) 3 (0.1%) 1 (0.1%) 0.046 0.83
MC (𝑛 = 841) 556 (43.9%) 285 (46.6%) 1.204 0.27
Other cancer (𝑛 = 101) 86 (1.7%) 15 (1.1%) 2.103 0.15
All cancer (𝑛 = 1977) 1354 (26.5%) 623 (46.9%) 205.683 <0.01
Total (𝑛 = 6,432) 5104 1328
Data are expressed as number (percentage) or mean ± SD unless otherwise specified.
Table 2: Univariate and multivariate analysis for PTC.
Independent variable Univariate Multivariate
OR (95% CI) 𝑃 value OR 𝑃 value
Age (⩾45 versus <45) 0.469 (0.420–0.525) 0.001 0.474 (0.423–0.532) 0.001
Gender (male versus female) 0.906 (0.790–1.039) 0.157 1.153 (0.999–1.330) 0.051
Hashimoto thyroiditis (HT versus non-HT) 2.701 (2.380–3.067) 0.001 2.725 (2.390–3.109) 0.001
46.2 ± 13.6 years, significantly younger than the non-HT
group.
Atotalof1,977thyroidectomyspecimens(30.7%of6,432)
were shown to harbor malignancy—mostly PTC (87.1% of all
malignancy). However, 823 cases (41.6% of all malignancy)
werebestclassifiedasmPTCand899specimens(45.5%ofall
malignancy) demonstrated a clinically relevant (>1cm)pap-
illary thyroid carcinoma. A low but detectable rate of FTC,
MTC, and ATC was also identified, but these rates were not
different in the HT cohort versus others (Table 1).
We next determined the prevalence of thyroid malig-
nancyinthyroidectomyspecimenswithorwithouthistologic
evidence of HT. In the HT group, 46.9% specimens were
f o u n dt oa l s oc o n t a i nat h y r o i dm a l i g n a n c yo fa n yp a t h o l o g -
ical type, compared to 26.5% of those without HT (𝑃 < 0.01,
Table 1). Interestingly, however, the difference in malignancy
rate was solely attributable to differences in the proportion
o fP T Ci nt h et w oc o h o r t s .O ft h e8 2 3p a t i e n t sw i t hm P T C ,
541 (10.6%) patients were in the non-HT group while 282
( 2 1 . 2 % )p a ti e n t sw e r ei nH Tg r o u p( Table 1). This finding was
consistent for crPTC as well. No difference was detected in
t h er a t eo fF T C ,M T C ,o ro t h e rm a l i g n a n c i e s( Table 1).
3.2. Prevalence of PTC (including mPTC and crPTC) in Var-
ious Subgroups. Due to the gender and age discrepancy in
n o n - H Ta n dH Tg r o u p ,w ed i v i d e dt h et o t a lp o p u l a t i o ni n t o
foursubcategoriesaccordingtothesexandagedifferences.It
wasshownconsistentlythattheprevalenceofPTCwashigher
in all Hashimoto’s cohorts in comparison with non-HT
groups(Figure 1(a)andsupplementaryTable1inSupplemen-
tary Material available online at http://dx.doi.org/10.1155/
2014/769294). Nearly all subgroups analysis showed similar
statistical findings for the prevalence of mPTC with the
exception of male under the age of 45 years (Figure 1(b) and
supplementary Table 1, 𝑃 = 0.05)a n df o rt h ep r e v a l e n c eo f
crPTC with one exception in male ⩾45 years (Figure 1(c) and
supplementary Table 1).
3.3. Risk Factor for PTCs. We used univariate and multivari-
ate analysis to determine whether the presence of HT would
be an independent risk factor for PTC. As it was shown in
Table 2,HTwasasignificantindependentriskfactorforPTC
withoddsratio2.725(95%CI,2.390–3.109).Theage⩾45years
was a protective risk factor for PTC with odds ratio 0.474
(95% CI, 0.423–0.532).
3.4. Local Lymph Node Metastasis (LNM) between Groups.
We next investigated the association of histologic HT upon
local metastatic disease as defined by lymph node metastasis
(LNM). Inclusive of all thyroid malignancy identified over 6
y e a r s ,t h ep r e s e n c eo fH Ts h o w e dan e u t r a le ff e c tu p o nl o c a l
LNM when thyroid cancer was present (𝑃 > 0.05, Figure 2
and supplementary Table 2).4 International Journal of Endocrinology
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Figure 1: The prevalence of PTC (a), mPTC (b), and crPTC (c) in different age and gender groups.
∗𝑃 < 0.05.
3.5. Risk Factors for LNM in PTCs. We then determined the
risk factors of LNM in PTCs. As shown in Table 3,w ef o u n d
thatmalegender,age<45years,focioftumor,andmaximum
diameter were risk factors for LNM in PTCs, while HT was
neitheraprotectivenorriskfactorforLNMinPTCswithOR
0.978, 95% CI (0.772–1.239) (Table 3).
3.6. Basic Characteristics of All PTCs between Non-HT and
HTGroups. AllcohortsevaluatedwithPTCdemonstratedan
associationwithyoungerageandfemalepredominanceinthe
Hashimoto’scohortcomparedwithnon-HTgroups.Thiswas
independentoftumorsize(Table 4).Nodifferencewasnoted
in the number of positive lymph nodes or the number of
specific tumor foci between HT and non-HT groups, respec-
tively. Interestingly, in all patients with Hashimoto’s disease,
thesizeofallidentifiedclinicallyrelevant(crPTC)wasgener-
ally smaller compared to those without Hashimoto’s disease.
In contrast, mPTCs were more often bilateral (though not
more often multifocal) in the HT cohort compared to non-
HT cohort.
4. Discussion
TherelationshipbetweenHashimoto’sthyroiditisandthyroid
malignancy has long been controversial. Differences in study
All thyroid
cancer
All PTC mPTC crPTC All
microcarcinoma
0.00
10.00
20.00
30.00
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(
%
)
Figure 2: Local lymph node metastasis in different groups. No
significance was found between HT and non-HT groups.
design, selection bias, and standardized approaches have led
to a mixed literature in this regard. Arguably, to best investi-
gate this important association, a large cohort of consec-
utive patients must be studied and all diagnoses—such as
Hashimoto’s disease and thyroid carcinoma—defined by
expert histopathologic analysis.International Journal of Endocrinology 5
Table 3: Univariate and multivariate analysis for LNM in PTCs.
Independent variable Univariate Multivariate
OR (95% CI) 𝑃 value OR (95% CI) 𝑃 value
Age (⩾45 versus <45) 0.439 (0.355–0.542) 0.001 0.455 (0.363–0.569) 0.001
Gender (Male versus Female) 1.723 (1.351–2.197) 0.001 1.544 (1.181–2.017) 0.001
Hashimoto thyroiditis (HT versus non-HT) 0.943 (0.760–1.170) 0.593 0.978 (0.772–1.239) 0.852
Foci of tumor 1.547 (1.367–1.750) 0.001 1.471 (1.293–1.673) 0.001
Maximum diameter 1.047 (1.038–1.057) 0.001 1.041 (1.031–1.051) 0.001
Table 4: Baseline data of PTC (mPTC and crPTC) between non-HT and HT group.
Non-HT HT Total 𝑃
All size of PTC (𝑛)1 1 4 1 5 8 1 1 7 2 2
Age at diagnosis 45.25 ± 13.63 41.40 ± 13.26 <0.01
<45y 560 (49.1%) 359 (61.8%) 919 (53.4%) <0.01
⩾45y 581 (50.9%) 222 (38.2%) 803 (46.6%)
Gender
Male 301 (26.4%) 46 (7.9%) 347 (20.2%) <0.01
Female 840 (73.6%) 535 (92.1%) 1375 (79.8%)
Number of positive lymph nodes 3.05 ± 0.192 2.66 ± 0.235 0.21
Foci of tumor 1.46 ± 0.025 1.46 ± 0.032 0.91
Maximum diameter (mm) 15.08 ± 0.358 13.92 ± 0.421 0.05
Bilateral tumor 241 (21.2%) 140 (24.1%) 381 0.16
Positive LNM 366 (32.1%) 179 (30.8%) 545 0.60
mPTC (𝑛)5 4 1 2 8 2 8 2 2
Age at diagnosis 47.21 ± 12.03 43.09 ± 13.04 <0.01
<45y 226 (41.8%) 159 (56.4%) 385 <0.01
⩾45y 315 (58.2%) 123 (43.6) 438
Gender
Male 121 (22.4%) 20 (7.1%) 141 <0.01
Female 420 (77.6%) 262 (92.9%) 682
Number of positive lymph nodes 1.71 ± 0.196 1.46 ± 0.237 0.42
Foci of tumor 1.32 ± 0.030 1.40 ± 0.043 0.11
Maximum diameter (mm) 6.02 ± 0.122 6.43 ± 0.165 0.05
Bilateral tumor 66 (12.2%) 52 (18.4%) 118 0.02
Positive LNM 116 (21.4%) 57 (20.2%) 173 0.68
crPTC (𝑛) 600 299 899
Age at diagnosis 43.48 ± 14.72 39.80 ± 13.29 <0.01
<45y 334 (55.7%) 200 (66.9%) 534 <0.01
⩾45y 266 (44.3%) 99 (33.1%) 365
Gender
Male 180 (30.0%) 26 (8.7%) 206
Female 420 (70.0%) 273 (91.3%) 693 <0.01
Number of positive lymph nodes 3.97 ± 0.285 3.62 ± 0.363 0.46
Foci of tumor 1.59 ± 0.039 1.51 ± 0.046 0.20
Maximum diameter (mm) 23.26 ± 0.467 20.98 ± 0.549 <0.01
Bilateral tumor 175 (29.3%) 88 (29.5%) 263 0.93
Positive LNM 250 (41.7%) 122 (40.8%) 372 0.80
Data are expressed as number (percentage) or mean ± SD.6 International Journal of Endocrinology
In this regard, we evaluated 6,432 consecutive thyroidec-
tomiesover6yearsfromasinglereferralinstitutioninChina,
revealingauniqueassociationbetweenHashimoto’sthyroidi-
tis and PTC. Particularly, Hashimoto’s thyroiditis increases
the risk of papillary thyroid carcinoma in affected subjects,
though it appears to impart no risk factor upon lymph
node metastasis and progressive disease. This association
was true both for mPTC and for crPTC, though it was not
detected for all other thyroid malignancies including follicu-
lar, medullary, and anaplastic thyroid carcinoma. These data
support previous pilot findings and suggest those with HT
may warrant increased attention for the development of
clinically relevant thyroid nodules given their higher risk of
malignancy.
A recent meta-analysis of this topic similarly demon-
strated that Hashimoto’s thyroiditis is correlated to the
presence of PTC, with carcinoma detected in 9.46∼36.60%
of patients with HT. In our study, the prevalence of PTC
i nt h eH Tc o h o r tw a s4 3 . 8 % ,w h i l ei nt h en o n - H Tg r o u p
t h ep r e v a l e n c ew a s2 2 . 4 % .Z h a n gs h o w e di na r e a sw h e r et h e
prevalence of HT was even higher the prevalence of PTC in
HT was also higher, reaching 58.3% compared to 44.3% in
non-HTgroupinthesameregion[22].Thissuggestsasimilar
influence of Hashimoto’s disease upon cancer risk across dif-
ferent populations despite variable incidence of malignancy.
Our study showed that HT was not only closely related to
an increased risk of crPTC, but also significantly related to
theriskofmPTC.ThissimilarrelationshiptobothcrPTCand
mPTC strengthens the translatability of our data and lessens
c o n c e r nf o rs e l e c t i o nb i a si no u rs t u d yp o p u l a t i o n .B e y o n d
its clinical importance, our data also lends support to the
hypothesis that microcellular dynamics (such as inflam-
mation) impact the development of thyroid malignancy
independent of nodule size.
Interestingly, although the coexistence of Hashimoto’s
disease appears related to increased risk of PTC, our results
s h o w e dH Tw a sn o tar i s kf a c t o rf o rL N Mi nP T C s .A n dt h e
maximum diameter of PTC seemed to be related to HT in
mPTC stage and conversely in the crPTC stage. The mecha-
nism behind this observation remains uncertain. In support,
however, Dvorkin has previously found that differentiated
thyroid cancer is similarly associated with less aggressive dis-
easeandbetteroutcomeinpatientswithcoexistingHT,while
Zhou has also found that HT is not a risk factor for occult
contralateral carcinoma in patients with unilateral mPTCs
[23]. Increasingly, clinical and basic investigations appear
to confirm the important influence of the body’s immune
system in relation to malignant disease. While infection and
immune response have been associated with an increased
risk of malignancy in illnesses such as hepatitis, it is equally
clearthatimmunologicinfluencecanalsopositivelyinfluence
malignant progression. This is perhaps best exemplified by
melanomaorbreastcarcinoma,wherenumerouscasereports
have described unusual, prolonged remissions or late recur-
r e n c e sw h i c hi m p l i c a t et h ei m m u n es y s t e ma sac a u s a t i v e
factor. Thus, while speculative, it is not unreasonable to
postulate that chronic inflammation of the thyroid may
increase malignant transformation, while nonetheless stim-
ulating an immunologic milieu in which tumor expansion
and malignant growth are less favored. Clinically, such a
h y po th e s i sw o ul dben ea r l yi m po s s i b l et op r o v e ,a sth e r ecu r -
rentlyexistnoimmunomodulatingtherapiesforHashimoto’s
disease by which one could study cancer prevalence and pro-
gression following a randomized intervention. However, it
isalsopossiblethatHTmaybethe“response”tothetumorin
genetically predisposed subjects and that this response may
slow down cancer progression. Regardless, these data
nonetheless provide insight into the complex interactions of
thyroidcellularbiochemistryandimmunologyandprovidea
stimulus for further investigation. We did find that male
gender, age<45 years, foci of tumor, and maximum diameter
were risk factors for LNM in PTCs in accordance with
another previous study [24].
The strength of our study relates to the size and unifor-
mity of our study cohort, as well as the strict histopathologic
definitions used for both Hashimoto’s thyroiditis and thyroid
m a l i g n a n c y .W ea l s oa n a l y z e dP T Ca c r o s st h ef u l ls p e c t r u m
of size, including evaluation of microcarcinomas no more
t h a n1c mi nd i a m e t e r .Th es i m i l a rr e l a t i o n s h i po fH Tt ob o t h
mPTC and crPTC is notable and speaks against selection or
s a m p l i n gb i a s .N o n e t h e l e s s ,w ea c k n o w l e d g et h el i m i t a t i o n s
to our investigation. Our study was retrospective and from
a single study center. We tried to eliminate further selection
bias by subanalyzing our total cohort by gender, age, size of
tumor, and using binary logistic regression method. We also
note that a relatively large percent (69.3%) of benign nodules
was resected. Most often, this was simply due to nodule size
more than 3cm or the presence of large multinodular goiters
(data not shown). While an ideal study would prospectively
investigate thyroidectomy histopathology among all patients
with nodular disease, it is unreasonable to routinely perform
thyroidectomies on all low risk patients [21], or those with
benign disease. We also note that HT itself was not a
thyroidectomy indication in our study. Recent data confirm
modest interobserver variability in cancer diagnosis [25],
which could reasonably suggest slight differences in transla-
tion of these data at other institutions.
In conclusion,these data providethemost extensive con-
secutiveanalysisoftherelationshipbetweenHashimoto’sthy-
roiditis and thyroid carcinoma, confirming an increased risk
of PTC in the setting of HT. While this increased risk appears
independent of PTC size, however, during more advanced
stage, HT was no longer a risk factor suggesting a poten-
tial protective effect of the inflammatory milieu upon the
progression of malignancy as defined by local LNM. These
data support previous pilot findings and suggest that patients
with HT may warrant increased attention for the develop-
ment of clinically relevant thyroid nodules given their higher
risk of malignancy.
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